심방세동 시장 : 시장 규모, 점유율, 동향 분석 보고서 - 치료 유형별, 최종 용도별, 지역별, 부문별 예측(2025-2033년)

Atrial Fibrillation Market Summary

The global atrial fibrillation market size was estimated at USD 26.89 billion in 2024 and is projected to reach USD 65.33 billion by 2033, growing at a CAGR of 10.44% from 2025 to 2033. The atrial fibrillation market is driven by a growing disease burden, rapid technological evolution in treatment and diagnostics, and the shift toward remote patient monitoring.

Companies capable of integrating these advancements into comprehensive care solutions are likely to lead market growth as clinical practices adapt to more efficient and patient-centric models. Strategic collaborations and acquisitions aimed at expanding access to innovative therapies will further accelerate market competitiveness.

The rising prevalence of atrial fibrillation, driven by aging populations and an increase in risk factors such as hypertension, diabetes, and obesity, is a major factor driving market growth. Atrial fibrillation is one of the leading causes of stroke and heart failure, prompting healthcare systems to prioritize early diagnosis and effective management. The growing patient pool is directly increasing demand for pharmacological treatments and advanced interventional procedures. In May 2024, the CDC highlighted atrial fibrillation (AFib) as the most common heart arrhythmia treated in the U.S. The number of Americans affected by AFib is expected to rise to 12.1 million by 2030. AFib plays a role in roughly 158,000 deaths each year and contributes to about 1 in 7 stroke cases.

Technological advancements in catheter ablation, 3D electro-anatomical mapping, and wearable ECG monitors are enhancing the precision and safety of atrial fibrillation treatments. Integration of artificial intelligence in arrhythmia detection and procedural planning is enabling faster, more accurate diagnosis and targeted therapy. These innovations are expanding treatment options to more patients while improving procedural outcomes and reducing recurrence rates. In April 2025, according to the Heart Rhythm Society (HRS), new research unveiled at Heart Rhythm 2025 showcased how artificial intelligence (AI) is enhancing safety and success rates in atrial fibrillation (AFib) treatments. The AI-driven DeePRISM model enables real-time waveform analysis during ablation procedures, improving outcomes for patients with persistent AFib. Experts highlighted AI's potential to transform electrophysiology by boosting clinical confidence and procedural precision.

The adoption of remote monitoring and telehealth platforms is changing how atrial fibrillation is managed, allowing continuous rhythm monitoring beyond clinical settings. Wearable ECG devices and smartphone-linked applications are providing real-time data to both patients and physicians, supporting proactive management and early intervention. Healthcare providers are leveraging these tools to monitor larger patient populations efficiently, especially for post-procedural follow-up and long-term care. In May 2025, researchers from the Melbourne Brain Centre developed an AI model that can detect silent atrial fibrillation (AF) in stroke patients by analyzing brain MRI scans. The technology showed promising accuracy (AUC 0.81) in differentiating AF-related strokes, offering a non-invasive and efficient detection method. This approach could potentially accelerate diagnosis and personalize stroke care by flagging hidden AF cases needing further cardiac evaluation.

The clustered column chart highlights the incremental rise in atrial fibrillation-related disability-adjusted life years (DALYs) and death rates across the Americas from 1990 to 2021. DALYs increased from 117.14 to 120.68 per 100,000 and death rates rose from 4.18 to 4.84 per 100,000. This reflects a persistent and growing burden on healthcare systems, particularly in regions where access to early detection and advanced treatment remains uneven. Without targeted healthcare policies to bridge these regional disparities, the clinical and economic strain of atrial fibrillation is projected to intensify in the coming decades.

Atrial fibrillation (AF) remains the most common sustained cardiac arrhythmia worldwide, posing a substantial challenge to healthcare systems due to its association with stroke, heart failure, and elevated mortality risks. Despite advancements in treatment options, the global prevalence of AF has more than doubled over the past three decades, driven by aging populations and lifestyle-related risk factors. In July 2025, according to The Lancet Regional Health Americas, regional disparities continue to shape the burden of atrial fibrillation across the continent. The U.S. experienced the highest rise in AF incidence and prevalence, while Canada saw a decline after age adjustments. Middle-income countries account for the majority of AF cases, facing rising incidence rates with limited screening infrastructure. Addressing these systemic gaps is critical to mitigating AF's escalating clinical and economic impact in the region.

Global Atrial Fibrillation Market Report Segmentation

This report forecasts revenue growth and provides at global, regional, and country levels an analysis of the latest trends in each of the sub-segments from 2021 to 2033. For this report, Grand View Research has segmented the global atrial fibrillation market report based on treatment type, end-use, and region:

• Treatment Type Outlook (Revenue, USD Million, 2021 - 2033)
• Pharmacological Treatment
  • Anti-arrhythmic Drugs
  • Anticoagulant Drugs
• Non-Pharmacological Treatment
  • Catheter Ablation
  • Radiofrequency
  • HIFU
  • Cryoablation
  • Microwave
  • Laser
  • Maze Surgery
  • Electric Cardioversion
• End-Use Outlook (Revenue, USD Million, 2021 - 2033)
• Hospitals
• Specialty Clinics
• Others
• Regional Outlook (Revenue, USD Million, 2021 - 2033)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • U.K.
  • Germany
  • France
  • Italy
  • Spain
  • Denmark
  • Sweden
  • Norway
• Asia Pacific
  • Japan
  • China
  • India
  • South Korea
  • Australia
  • Thailand
• Latin America
  • Brazil
  • Argentina
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
  • 1.1.1. Segment scope
  • 1.1.2. Estimates and forecast timeline
• 1.2. Research Methodology
• 1.3. Information Procurement
  • 1.3.1. Purchased database
  • 1.3.2. GVR's internal database
  • 1.3.3. Secondary sources
  • 1.3.4. Primary research
  • 1.3.5. Details of primary research
• 1.4. Information or Data Analysis
  • 1.4.1. Data analysis models
• 1.5. Market Formulation & Validation
• 1.6. Model Details
• 1.7. Research Assumptions
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Treatment type outlook
  • 2.2.2. End use outlook
• 2.3. Competitive Insights

Chapter 3. Global Atrial Fibrillation Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
  • 3.2.2. Market restraint analysis
• 3.3. Global Atrial Fibrillation: Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
  • 3.3.2. PESTLE Analysis
• 3.4. Technology Landscape
• 3.5. Case Study Analysis

Chapter 4. Global Atrial Fibrillation Market Segment Analysis, By Treatment Type, 2021 - 2033 (USD Million)

• 4.1. Definition and Scope
• 4.2. Treatment Type Market Share Analysis, 2024 & 2033
• 4.3. Segment Dashboard
• 4.4. Global Atrial Fibrillation Market, by Treatment Type, 2021 to 2033
• 4.5. Pharmacological Treatment
  • 4.5.1. Pharmacological treatment market estimates and forecasts, 2021 to 2033 (USD Million)
  • 4.5.2. Anti-arrhythmic Drugs
    • 4.5.2.1. Anti-arrhythmic drugs market estimates and forecasts, 2021 to 2033 (USD Million)
  • 4.5.3. Anticoagulant Drugs
    • 4.5.3.1. Anticoagulant drugs market estimates and forecasts, 2021 to 2033 (USD Million)
• 4.6. Non-Pharmacological Treatment
  • 4.6.1. Non-pharmacological treatment market estimates and forecasts, 2021 to 2033 (USD Million)
  • 4.6.2. Catheter Ablation
    • 4.6.2.1. Catheter ablation market estimates and forecasts, 2021 to 2033 (USD Million)
    • 4.6.2.2. Radiofrequency
      • 4.6.2.2.1. Radiofrequency market estimates and forecasts, 2021 to 2033 (USD Million)
    • 4.6.2.3. HIFU
      • 4.6.2.3.1. HIFU market estimates and forecasts, 2021 to 2033 (USD Million)
    • 4.6.2.4. Cryoablation
      • 4.6.2.4.1. Cryoablation market estimates and forecasts, 2021 to 2033 (USD Million)
    • 4.6.2.5. Microwave
      • 4.6.2.5.1. Microwave market estimates and forecasts, 2021 to 2033 (USD Million)
    • 4.6.2.6. Laser
      • 4.6.2.6.1. Laser market estimates and forecasts, 2021 to 2033 (USD Million)
  • 4.6.3. Maze Surgery
    • 4.6.3.1. Maze surgery market estimates and forecasts, 2021 to 2033 (USD Million)
  • 4.6.4. Electric Cardioversion
    • 4.6.4.1. Electric cardioversion market estimates and forecasts, 2021 to 2033 (USD Million)

Chapter 5. Global Atrial Fibrillation Market Segment Analysis, By End Use, 2021 - 2033 (USD Million)

• 5.1. Definition and Scope
• 5.2. End Use Market Share Analysis, 2024 & 2033
• 5.3. Segment Dashboard
• 5.4. Global Atrial Fibrillation Market, by End Use, 2021 to 2033
• 5.5. Hospitals
  • 5.5.1. Hospitals market estimates and forecasts, 2021 to 2033 (USD Million)
• 5.6. Specialty Clinics
  • 5.6.1. Specialty Clinics market estimates and forecasts, 2021 to 2033 (USD Million)
• 5.7. Others
  • 5.7.1. Others market estimates and forecasts, 2021 to 2033 (USD Million)

Chapter 6. Atrial Fibrillation Market Segment Analysis, By Region, 2021 - 2033 (USD Million)

• 6.1. Regional Market Share Analysis, 2024 & 2033
• 6.2. Regional Market Dashboard
• 6.3. Regional Market Snapshot
• 6.4. Atrial Fibrillation Market Share by Region, 2024 & 2033:
• 6.5. North America
  • 6.5.1. North America atrial fibrillation market, 2021 - 2033 (USD Million)
  • 6.5.2. U.S.
    • 6.5.2.1. Key Country Dynamics
    • 6.5.2.2. Regulatory Scenario
    • 6.5.2.3. Competitive Scenario
    • 6.5.2.4. U.S. atrial fibrillation market, 2021 - 2033 (USD Million)
  • 6.5.3. Canada
    • 6.5.3.1. Key Country Dynamics
    • 6.5.3.2. Regulatory Scenario
    • 6.5.3.3. Competitive Scenario
    • 6.5.3.4. Canada atrial fibrillation market, 2021 - 2033 (USD Million)
  • 6.5.4. Mexico
    • 6.5.4.1. Key Country Dynamics
    • 6.5.4.2. Regulatory Scenario
    • 6.5.4.3. Competitive Scenario
    • 6.5.4.4. Mexico atrial fibrillation market, 2021 - 2033 (USD Million)
• 6.6. Europe
  • 6.6.1. Europe atrial fibrillation market, 2021 - 2033 (USD Million)
  • 6.6.2. UK
    • 6.6.2.1. Key Country Dynamics
    • 6.6.2.2. Regulatory Scenario
    • 6.6.2.3. Competitive Scenario
    • 6.6.2.4. UK atrial fibrillation market, 2021 - 2033 (USD Million)
  • 6.6.3. Germany
    • 6.6.3.1. Key Country Dynamics
    • 6.6.3.2. Regulatory Scenario
    • 6.6.3.3. Competitive Scenario
    • 6.6.3.4. Germany atrial fibrillation market, 2021 - 2033 (USD Million)
  • 6.6.4. France
    • 6.6.4.1. Key Country Dynamics
    • 6.6.4.2. Regulatory Scenario
    • 6.6.4.3. Competitive Scenario
    • 6.6.4.4. France atrial fibrillation market, 2021 - 2033 (USD Million)
  • 6.6.5. Italy
    • 6.6.5.1. Key Country Dynamics
    • 6.6.5.2. Regulatory Scenario
    • 6.6.5.3. Competitive Scenario
    • 6.6.5.4. Italy atrial fibrillation market, 2021 - 2033 (USD Million)
  • 6.6.6. Spain
    • 6.6.6.1. Key Country Dynamics
    • 6.6.6.2. Regulatory Scenario
    • 6.6.6.3. Competitive Scenario
    • 6.6.6.4. Spain atrial fibrillation market, 2021 - 2033 (USD Million)
  • 6.6.7. Norway
    • 6.6.7.1. Key Country Dynamics
    • 6.6.7.2. Regulatory Scenario
    • 6.6.7.3. Competitive Scenario
    • 6.6.7.4. Norway atrial fibrillation market, 2021 - 2033 (USD Million)
  • 6.6.8. Sweden
    • 6.6.8.1. Key Country Dynamics
    • 6.6.8.2. Regulatory Scenario
    • 6.6.8.3. Competitive Scenario
    • 6.6.8.4. Sweden atrial fibrillation market, 2021 - 2033 (USD Million)
  • 6.6.9. Denmark
    • 6.6.9.1. Key Country Dynamics
    • 6.6.9.2. Regulatory Scenario
    • 6.6.9.3. Competitive Scenario
    • 6.6.9.4. Denmark atrial fibrillation market, 2021 - 2033 (USD Million)
• 6.7. Asia Pacific
  • 6.7.1. Japan
    • 6.7.1.1. Key Country Dynamics
    • 6.7.1.2. Regulatory Scenario
    • 6.7.1.3. Competitive Scenario
    • 6.7.1.4. Japan atrial fibrillation market, 2021 - 2033 (USD Million)
  • 6.7.2. China
    • 6.7.2.1. Key Country Dynamics
    • 6.7.2.2. Regulatory Scenario
    • 6.7.2.3. Competitive Scenario
    • 6.7.2.4. China atrial fibrillation market, 2021 - 2033 (USD Million)
  • 6.7.3. India
    • 6.7.3.1. Key Country Dynamics
    • 6.7.3.2. Regulatory Scenario
    • 6.7.3.3. Competitive Scenario
    • 6.7.3.4. India atrial fibrillation market, 2021 - 2033 (USD Million)
  • 6.7.4. Australia
    • 6.7.4.1. Key Country Dynamics
    • 6.7.4.2. Regulatory Scenario
    • 6.7.4.3. Competitive Scenario
    • 6.7.4.4. Australia atrial fibrillation market, 2021 - 2033 (USD Million)
  • 6.7.5. South Korea
    • 6.7.5.1. Key Country Dynamics
    • 6.7.5.2. Regulatory Scenario
    • 6.7.5.3. Competitive Scenario
    • 6.7.5.4. South Korea atrial fibrillation market, 2021 - 2033 (USD Million)
  • 6.7.6. Thailand
    • 6.7.6.1. Key Country Dynamics
    • 6.7.6.2. Regulatory Scenario
    • 6.7.6.3. Competitive Scenario
    • 6.7.6.4. Thailand atrial fibrillation market, 2021 - 2033 (USD Million)
• 6.8. Latin America
  • 6.8.1. Brazil
    • 6.8.1.1. Key Country Dynamics
    • 6.8.1.2. Regulatory Scenario
    • 6.8.1.3. Competitive Scenario
    • 6.8.1.4. Brazil atrial fibrillation market, 2021 - 2033 (USD Million)
  • 6.8.2. Argentina
    • 6.8.2.1. Key Country Dynamics
    • 6.8.2.2. Regulatory Scenario
    • 6.8.2.3. Competitive Scenario
    • 6.8.2.4. Argentina atrial fibrillation market, 2021 - 2033 (USD Million)
• 6.9. MEA
  • 6.9.1. South Africa
    • 6.9.1.1. Key Country Dynamics
    • 6.9.1.2. Regulatory Scenario
    • 6.9.1.3. Competitive Scenario
    • 6.9.1.4. South Africa atrial fibrillation market, 2021 - 2033 (USD Million)
  • 6.9.2. Saudi Arabia
    • 6.9.2.1. Key Country Dynamics
    • 6.9.2.2. Regulatory Scenario
    • 6.9.2.3. Competitive Scenario
    • 6.9.2.4. Saudi Arabia atrial fibrillation market, 2021 - 2033 (USD Million)
  • 6.9.3. UAE
    • 6.9.3.1. Key Country Dynamics
    • 6.9.3.2. Regulatory Scenario
    • 6.9.3.3. Competitive Scenario
    • 6.9.3.4. UAE atrial fibrillation market, 2021 - 2033 (USD Million)
  • 6.9.4. Kuwait
    • 6.9.4.1. Key Country Dynamics
    • 6.9.4.2. Regulatory Scenario
    • 6.9.4.3. Competitive Scenario
    • 6.9.4.4. Kuwait atrial fibrillation market, 2021 - 2033 (USD Million)

Chapter 7. Competitive Landscape

• 7.1. Recent Developments & Impact Analysis, By Key Market Participants
• 7.2. Company Categorization
• 7.3. Company Profiles
  • 7.3.1. AtriCure Inc.
    • 7.3.1.1. Company overview
    • 7.3.1.2. Financial performance
    • 7.3.1.3. Product benchmarking
    • 7.3.1.4. Strategic initiatives
  • 7.3.2. Boehringer Ingelheim GmbH
    • 7.3.2.1. Company overview
    • 7.3.2.2. Financial performance
    • 7.3.2.3. Product benchmarking
    • 7.3.2.4. Strategic initiatives
  • 7.3.3. Boston Scientific Corporation.
    • 7.3.3.1. Company overview
    • 7.3.3.2. Financial performance
    • 7.3.3.3. Product benchmarking
    • 7.3.3.4. Strategic initiatives
  • 7.3.4. Bristol- Myers Squibb Corporation
    • 7.3.4.1. Company overview
    • 7.3.4.2. Financial performance
    • 7.3.4.3. Product benchmarking
    • 7.3.4.4. Strategic initiatives
  • 7.3.5. Cardio Focus Inc.
    • 7.3.5.1. Company overview
    • 7.3.5.2. Financial performance
    • 7.3.5.3. Product benchmarking
    • 7.3.5.4. Strategic initiatives
  • 7.3.6. Sanofi Aventis
    • 7.3.6.1. Company overview
    • 7.3.6.2. Financial performance
    • 7.3.6.3. Product benchmarking
    • 7.3.6.4. Strategic initiatives
  • 7.3.7. Biosense Webster Inc.
    • 7.3.7.1. Company overview
    • 7.3.7.2. Financial performance
    • 7.3.7.3. Product benchmarking
    • 7.3.7.4. Strategic initiatives
  • 7.3.8. Endoscopic Technologies Inc.
    • 7.3.8.1. Company overview
    • 7.3.8.2. Financial performance
    • 7.3.8.3. Product benchmarking
    • 7.3.8.4. Strategic initiatives
  • 7.3.9. Abbott (St. Jude Medical Inc.)
    • 7.3.9.1. Company overview
    • 7.3.9.2. Financial performance
    • 7.3.9.3. Product benchmarking
    • 7.3.9.4. Strategic initiatives
  • 7.3.10. Johnsons & Johnson
    • 7.3.10.1. Company overview
    • 7.3.10.2. Financial performance
    • 7.3.10.3. Product benchmarking
    • 7.3.10.4. Strategic initiatives